Q-linea AB (QLINEA) Fair Value & Analysis
Healthcare · SE · Market cap 317M SEK
Fair value as of: Jul 16, 2026
From 3 valuation models · updated yesterday
Fair value updated Jul 16, 2026, revised from kr 80.27 to kr 9.41 (−88.3%) since Jun 24, 2026. Share price −5.0% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 14.85 – kr 56.96 · fair‑value band kr 4.80 – kr 13.93 · the kr 17.10 price screens above the kr 9.41 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Q-linea AB (QLINEA) currently trades at kr 17.10, while our model-based Fair Value estimate is kr 9.41, implying the stock looks roughly 45.0% overvalued today. We read business quality at 27/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 11.8M SEK. Revenue declined 57.4% year over year. It earns a return on equity of -80.5%. The balance sheet holds a net cash position of 250M SEK. Fundamentals as of Jul 16, 2026
Our scenario range runs from kr 4.80 (bear case) to kr 13.93 (bull case); at kr 17.10, the current price sits above that range. The share trades about 77% below its 52-week high and 18% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -39% fair-value upside, at -45%, QLINEA screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture technology. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Q-linea AB reported revenue of kr 11.1M in FY2025 versus kr 9.3M in FY2021, a compound +4.4%/yr. Reported net income was −kr 182M in FY2025.
Is QLINEA fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABL | €76.90 | €78.64 | +2% |
| Stryker Corporation SYK | $308.84 | $187.83 | -39% |
| Medtronic plc MDTC34 | R$203.91 | R$27.47 | -87% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EWL | €74.82 | €32.56 | -56% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| GE HealthCare Technologies Inc GEHC | $60.64 | $65.03 | +7% |
| Koninklijke Philips N.V 1PHIA | €24.31 | €9.97 | -59% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥143.50 | ¥111.50 | -22% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Q-linea AB (QLINEA) undervalued?
What is the fair value of QLINEA?
What is the quality score of QLINEA?
What is the revenue of Q-linea AB (QLINEA)?
What is the net profit margin of QLINEA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Q-linea AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.